UC Health - Anschutz Medical Campus
Welcome,         Profile    Billing    Logout  
 6 Trials 
10 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Badesch, David B
CAPACITY, NCT04084678: A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

Terminated
3
10
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Hypertension, Connective Tissue Disease, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease, Pulmonary Arterial Hypertension
04/23
04/23
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
NCT05798923: A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension

Recruiting
2
15
US
LAM-001
OrphAI Therapeutics
Pulmonary Hypertension
12/24
12/25
PHAR, NCT04071327: Pulmonary Hypertension Association Registry

Recruiting
N/A
3000
US
Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
10/25
10/25
Bull, Todd M
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
NCT03409588: Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

Recruiting
2
20
US
Adempas, Riociguat
University of Colorado, Denver, Bayer
Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery
12/24
12/24
CHORUS, NCT06259292: Comprehensive HHT Outcomes Registry of the United States

Recruiting
N/A
10000
US
Cure HHT, Augusta University, The Cleveland Clinic, Mayo Clinic, Massachusetts General Hospital, Columbia University, Oregon Health and Science University, University of California, Los Angeles, University of California, San Francisco, University of Colorado, Denver, University of North Carolina, Chapel Hill, University of Pennsylvania, University of Texas, University of Utah, Washington University School of Medicine, Yale University, Health Resources and Services Administration (HRSA), Children's Hospital of Philadelphia
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
11/33
11/33
PHAR, NCT04071327: Pulmonary Hypertension Association Registry

Recruiting
N/A
3000
US
Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
10/25
10/25
Marco, Teresa De
PHAR, NCT04071327: Pulmonary Hypertension Association Registry

Recruiting
N/A
3000
US
Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
10/25
10/25

Download Options